Commentary on the Royalty Pharma Ruling of the CJEU of 30 April 2020. Full text: Comunicaciones ENG oct 2020 pag
The reference price system and annual reference price orders are intended to contribute to the sustainability of the SNS. They should also promote the right balance between innovative generic/biosimilar, competition and competitiveness in the pharmaceutical and health market. Price decisions […]
BIOSIMILAR AND GENERIC DRUGS With the document of statements, the CEFI Foundation analyses each of the specific measures proposed in the Plan in detail but, in general, it believes that in the draft of the plan, the basic principles of […]
CEFI, as a member of the Interministerial Commission to act against activities which infringe intellectual and industrial property rights, backs the institutional anti-counterfeiting campaign carried out by the Ministry of Industry, Trade and Tourism together with the Spanish Patent and […]
Farmaindustria has published an interesting decalogue on the value of brands. It is important to strengthen the role of brands as industrial property and business assets that strengthen competitiveness in the market and inform us about their attributes. They highlight […]
A foundation for promoting and supporting research and technological development, especially regarding the pharmaceutical industry
Nuestra entidad se encuentra adherida a Confianza Online (Asociación sin ánimo de lucro), inscrita en el Registro Nacional de Asociaciones Grupo 1, Sección 1, número nacional 594400, CIF G85804011, Calle la Palma 59, Bajo A., 28015 Madrid (España), teléfono (+34) 91 309 13 47 y fax (+34) 91 402 83 39 (www.confianzaonline.es).
